CoChat

Reduced-intensity allogeneic transplantation for myeloma: reality bites

Stewart, A. Keith · 2009 · Blood
Cited by 35

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Like a second marriage, the continued pursuit of safe and effective allogeneic stem cell transplantation for myeloma appears to be a triumph of hope over experience. In this issue of Blood , Bruno et al[1][1] and Rotta et al[2][2] (along with a previous article by Rosinol et al[3][3]) describe the

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2008-12-173526

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma

    Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omedè, P., Baldi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065464 · Cited by 501 · cited 1×

    “For low-risk patients (absence of t(4;14), normal chromosome 13 and 17, and low beta – 2- microglobulin) treated by conventional chemotherapy followed by tandem AST, 75% are alive at 5 years.”
    Method

Show all 1 references

Research works printed but not linked: 10

  1. Bruno, 2009, Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo., Blood, 113, 3375, 10.1182/blood-2008-07-167379 · DOI
  2. Rotta, 2009, Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting., Blood, 113, 3383, 10.1182/blood-2008-07-170746 · DOI
  3. Rosinol, 2008, A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma., Blood, 112, 3591, 10.1182/blood-2008-02-141598 · DOI · Paper page
  4. Garban, 2006, Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99–03 trial) with tandem autologous stem cell transplantation (IFM99–04 trial) in high-risk de novo multiple myeloma., Blood, 107, 3474, 10.1182/blood-2005-09-3869 · DOI · Paper page
  5. Barlogie, 2006, Thalidomide and hematopoietic-cell transplantation for multiple myeloma., N Engl J Med, 354, 1021, 10.1056/NEJMoa053583 · DOI · Paper page
  6. Attal, 2006, Maintenance therapy with thalidomide improves survival in patients with multiple myeloma., Blood, 108, 3289, 10.1182/blood-2006-05-022962 · DOI · Paper page
  7. Barlogie, 2006, Long-term outcome results of the first tandem autotransplant trial for multiple myeloma., Br J Haematol, 135, 158, 10.1111/j.1365-2141.2006.06271.x · DOI · Paper page
  8. Lacy, 2007, Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma., Mayo Clin Proc, 82, 1179, 10.4065/82.10.1179 · DOI
  9. Avet-Loiseau, 2007, Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome., Blood, 109, 3489, 10.1182/blood-2006-08-040410 · DOI · Paper page
  10. Barlogie, 2008, Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities., Blood, 112, 3115, 10.1182/blood-2008-03-145235 · DOI · Paper page

Cited by

See all 35

Metadata

Authors
Stewart, A. K.
Venue
Blood
Published
2009-04-02
Volume
113
Issue
14
Pages
3135-3136
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2128880706
Cited by
35
References
1
FWCI
1.19
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Reduced-intensity allogeneic transplantation for myeloma: reality bites. https://app.cochat.ai/papers/10.1182/blood-2008-12-173526
The paper
Stewart, A. K. (2009). Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood. https://doi.org/10.1182/blood-2008-12-173526

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.